Idarubicin in Refractory Acute Leukemia | Zendy

H.H. Fülle | Zendy; K.P. Hellriegel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Idarubicin in Refractory Acute Leukemia

Author(s) -

H.H. Fülle,

K.P. Hellriegel

Publication year - 1986

Publication title -

oncology research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.553

H-Index - 48

eISSN - 2296-5262

pISSN - 2296-5270

DOI - 10.1159/000215992

Subject(s) - idarubicin , medicine , etoposide , aplasia , chemotherapy , leukemia , refractory (planetary science) , regimen , salvage therapy , acute leukemia , surgery , cytarabine , oncology , gastroenterology , biology , astrobiology

10 patients with resistant or relapsed acute leukemia (9 AML, 1 ALL) were treated with idarubicin (4-demethoxydaunorubicin) in combination with cytosine arabinoside +/- etoposide. All patients had been heavily pretreated. 9 AML-patients had previously received 2-4 cycles of TAD-9 regimen. 2 complete and 1 partial remission were achieved. 1 patient died from septicemia in bone marrow aplasia without leukemic cells. 6 patients did not respond to idarubicin-based salvage treatment. The median survival from start of therapy was 4 months. Idarubicin-based combination chemotherapy is effective in relapsed acute leukemia, even in patients intensively pretreated with anthracyclines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research